Solvotrin Therapeutics is a drug development company focused on chemical modifications of known drugs. SolvotrinÕs intellectual property offers a major opportunity with novel, patent-protected new chemical entities at the cutting edge of therapeutics. It arises from the discovery in Trinity College Dublin of the first ÒtrueÓ aspirin prodrugs. SolvotrinÕs patented linker releases aspirin and various associated molecules post absorption with the required speed and recovery to improve effectiveness, while avoiding the direct gut toxicity associated with aspirin. SolvotrinÕs lead product, ST1406 (also known as ACTIVE IRONª) is clinically proven to outperform market leading oral iron supplements in an iron deficiency market. Together with Scientists at Trinity College Dublin we have developed a groundbreaking new method of delivering iron which improves absorption and reduces negative gastrointestinal side-effects. The new technology uses a unique iron-whey protein complex to ensure iron is released in the small intestine (at the DMT-1, the bodyÕs normal iron gateway), where it is most readily absorbed, instead of the stomach where it causes oxidative stress and triggers gastric side-effects. Studies confirm the new Active Iron formulation doubles the amount of iron absorbed while being so gentle on the gastric system it can be taken on an empty stomach. Active Iron is tough on tiredness because its advanced formulation improves iron absorption and it is also kind on you. As Active Iron only uses denatured whey-protein and encapsulated ferrous sulphate Ð this means that it is suitable for vegetarians.